A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination with Pembrolizumab in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

NCT #
Condition(s)
Lung Cancer (NSCLC), Lung Cancer (SCLC), Skin Cancer/ Melanoma
Molecular Target(s)
CD137, PD-1, PD-L1
Drug Classification(s)
Molecular Targeted Therapy
Agents(s)
CTX-471
Phase(s)
I

Mechanism of Action

CTX-471 is a fully humanized IgG4 agonist antibody for CD-137, also known as 4-1BB, a costimulatory factor for T cells and NK cells.

Purpose

  • How much of the study agent alone or in combination with Pembrolizumab can be given with an acceptable level of side effects
  • Learn about the safety and tolerability of the study agent
  • How much of the study agent alone or in combination with Pembrolizumab is absorbed into the blood and how fast it is removed
  • How proteins that indicate the status of your disease are affected with the use of the study agent alone or in combination with Pembrolizumab
  • If your body develops proteins that work against the study agent alone or in combination with Pembrolizumab
  • If research tests can be used in the future to predict who will benefit from CTX-471

Location

Mary Crowley Cancer Research - Medical City Dallas

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.

7777 Forest Lane,
Building C-707
Dallas, TX 75230

972.566.3000